The $6m investment expands the group's healthcare portfolio.

这笔600万美元的投资扩大了该集团的医疗保健产品组合。

Boustead Singapore

新加坡宝鼎

is expanding its healthcare technology business after investing $6m for a 60% stake in Singapore-based medical technology company UroMedTech.

在投资600万美元收购新加坡医疗科技公司UroMedTech 60%的股权后，正在扩大其医疗保健技术业务。

Through Boustead Medical Care Holdings (BMCH), the group added robotic prostate cancer diagnostics to the its healthcare portfolio.

通过Boustead医疗护理控股公司（BMCH），该集团在其医疗保健产品组合中增加了机器人前列腺癌诊断服务。

UroMedTech develops UroMaster, a robotic MRI-ultrasound fusion biopsy platform used in prostate cancer diagnosis.

UroMedTech开发了UroMaster，这是一个用于前列腺癌诊断的机器人MRI-超声融合活检平台。

The company said the system has secured regulatory approvals in Singapore, Malaysia, Australia, and other Asian markets, and is deployed across seven hospitals and clinical sites in Singapore, Malaysia, Thailand, and the Philippines.

该公司表示，该系统已在新加坡、马来西亚、澳大利亚及其他亚洲市场获得监管批准，并在新加坡、马来西亚、泰国和菲律宾的七家医院及临床机构部署使用。

Boustead said the acquisition will support the commercialisation of UroMaster, the development of new capabilities such as AI-assisted pathology and focal therapy, and expansion into overseas markets through BMCH's regional distribution network.

Boustead表示，此次收购将支持UroMaster的商业化，推动人工智能辅助病理学和局部治疗等新能力的开发，并通过BMCH的区域分销网络拓展海外市场。

'We founded the company with a vision of transforming the prostate cancer journey from a fragmented process into a seamless, technology-enabled experience for both clinicians and patients,” said UroMedTech CEO Wilson Gao.

“我们创立这家公司，旨在将前列腺癌的诊疗历程从支离破碎的流程转变为面向临床医生和患者的无缝、技术赋能的体验。”UroMedTech首席执行官Wilson Gao表示。

Gao said the company has filed for regulatory approvals in the United States and the European Union and plans to seek approvals in additional markets over the next few years.

高表示，该公司已向美国和欧盟提交监管审批申请，并计划在未来几年内寻求在其他市场的批准。

Following the acquisition, UroMedTech will continue operating under its existing brand whilst working with BMCH on research and development, clinical partnerships and regulatory approvals.

收购完成后，UroMedTech 将在继续以现有品牌运营的同时，与 BMCH 在研发、临床合作及监管审批方面展开合作。

Boustead said the transaction is not expected to have a material impact on the group's profitability, earnings per share or tangible net asset value per share for the financial year ending 31 March 2027.

Boustead 表示，预计该交易不会对截至 2027 年 3 月 31 日止财政年度的集团盈利能力、每股收益或每股有形净资产价值产生重大影响。